Oncolytics Biotech® Announces Public Offering of Common Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street dips after strong jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
UPDATE: Oncolytics Biotech (ONCY) Prices 1.37M Common Stock Offering at $5.83/Share
June 1, 2018 9:14 AM EDT(Updated - June 1, 2018 9:15 AM EDT)
(Update corrects company name in headline)
Oncolytics Biotech® Inc. (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the pricing of its underwritten public offering of 1,372,213 common shares (the Offering). The shares are being sold at a public offering price of USD $5.83 per share. The gross offering proceeds to the Company from this Offering are expected to be approximately USD $8,000,000 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares are being... More
